Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
Abstract Introduction Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiated secukinumab for the treatment of patie...
Main Authors: | Prashanth Sunkureddi, Dominick Latremouille-Viau, Mark K. Meiselbach, Jipan Xie, Peter Hur, Reeti Joshi |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-01-01
|
Series: | Rheumatology and Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s40744-018-0137-z |
Similar Items
-
Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review
by: Reeti Joshi, et al.
Published: (2019-01-01) -
Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study
by: Karin Bengtsson, et al.
Published: (2017-05-01) -
Demographic, clinical, laboratory and treatment characteristics of spondyloarthritis patients with and without acute anterior uveitis
by: Marcelo Gehlen, et al. -
Treatment of psoriatic arthritis with secukinumab: a case series
by: Stefania Nicola, et al.
Published: (2018-11-01) -
Treatment with secukinumab in multi-comorbid patients with psoriatic arthritis
by: Ombretta Viapiana, et al.
Published: (2018-12-01)